KPRX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own KPRX shares is 19, representing 48.34% of the company's common stock.

VANGUARD GROUP INC, in the last quarter, reduced its stake in KPRX by -12.72% restricting it's holding to 67.21 thousand shares of worth nearly $31.00K. RENAISSANCE TECHNOLOGIES LLC also lessened -55.31% of the KPRX shares from its portfolio, reducing its holding to 41.84 thousand shares of worth $20.00K. MORGAN STANLEY also shunned KPRX shares holding by -4.58% last quarter which brought its holding to 333 shares worth -.

As per its latest 13F filing, GEODE CAPITAL MANAGEMENT, LLC increased its stake in KPRX by 3.28% in the last quarter. The institutional holder raised its holding to 547.13 thousand shares having worth more than $257.00K. CITADEL ADVISORS LLC also added 100% more shares of KPRX to its portfolio, raising its holding to 46.44 thousand shares of worth $22.00K. UBS GROUP AG also increased its KPRX shares holding by 100% which brought its holding to 28.86 thousand shares worth $13.00K.

The insider with the most stakes in KPRX is FROM STEPHEN , President and CEO at the company. Additionally, KPRX stock is highly held by 10 percent owner ARMISTICE CAPITAL, LLC and Chief Medical Officer Wirostko Barbara among others.

Company executives, directors, and other insiders own 2.31% percent of Kiora Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which KPRX insiders have sold stock, totaling 0 shares. Insiders that have sold shares include ARMISTICE CAPITAL, LLC, GOLDBERG MORTON, and FROM STEPHEN.

There have been 5 transaction(s) during the past 6-months in which Kiora Pharmaceuticals, Inc. insiders have bought stock, totalling 12500 shares

Around 24.11K Kiora Pharmaceuticals, Inc. shares are held by insiders, which represents about 2.31% of KPRX stock.

KPRX President and CEO, FROM STEPHEN holds the largest portfolio of the company's shares. KPRX shares owned by FROM total nearly 1.03 million.

GEODE CAPITAL MANAGEMENT, LLC is the largest institutional owner in KPRX which holds 547.13 thousand shares worth $257.00K or 0.73% of the total KPRX shares outstanding followed by VANGUARD GROUP INC with ownership of 67.21 thousand shares representing 0.09% of the KPRX ownership. CITADEL ADVISORS LLC is the third largest stakeholder with 46.44 thousand shares or 0.06% of the ownership worth more than $22.00K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the KPRX is concerned, it is a stock which is not optionable.

Number of KPRX shares short is 3.61K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 3.00M shares of KPRX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, KPRX has 1.36M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for KPRX is 0.27.